JERSEY CITY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME(ibrexafungerp tablets) to the consumer level in the US market due to potential cross contamination with a non-antibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the…Read More
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME ibrexafungerp tablets due to potential for cross contamination with a nonantibacterial lactam drug substance
